A coroner has concluded that a Worcestershire man died after stopping smoking caused dangerous levels of his prescribed medication to build up in his body, highlighting concerns over the lack of clinical guidance for patients taking certain psychiatric drugs.
Jack Burton, 29, who lived in Worcester, died on October 7, 2025, just days after deciding to quit smoking while on a family holiday in Scarborough.
An inquest heard that the sudden change in his smoking habits significantly altered how his body processed the antipsychotic medication clozapine, resulting in toxic blood concentrations.
Smoking Habit Had Direct Impact on Medication Dose
Mr Burton had been diagnosed with paranoid schizophrenia and was receiving treatment with clozapine under the care of a community psychiatrist.
Because cigarette smoking reduces the effectiveness of the medication by increasing its breakdown in the body, he had been prescribed a nightly dose of 525mg while he remained a heavy smoker.
Evidence presented during the hearing showed that the dosage was appropriate while he continued smoking.
However, once he abruptly stopped, the medication was no longer metabolized at the same rate, causing blood levels to rise to a dangerous point.
The inquest heard that the prescribed dose would be considered hazardous for a non-smoker and carried a heightened risk of seizures.
Coroner Identifies Smoking Cessation as Likely Cause of Toxicity
Deborah Lakin, the coroner for Worcestershire, determined that Mr Burton’s decision to stop smoking most likely triggered the fatal increase in clozapine levels.
In a Prevention of Future Deaths report, she stated that if Mr Burton had intended to quit smoking, he should have informed his treating psychiatrist so that his medication dosage could have been reduced accordingly.
The report stressed that appropriate adjustments may have prevented the fatal outcome.
Concerns Raised Over Lack of National Guidance
The inquest also exposed uncertainties surrounding the advice given to patients taking clozapine who reduce or stop smoking.
Ms Lakin noted that evidence from two consultant psychiatrists revealed conflicting views about the medical significance of reducing smoking compared with stopping altogether.
According to the coroner, those differing opinions reflected the absence of standardized guidance available to healthcare professionals on managing clozapine doses when patients change their smoking habits.
Questions Over Documentation and Patient Discussions
Further concerns emerged regarding how clinicians record conversations about medication risks and side effects.
During the proceedings, it was unclear whether Mr Burton had sought advice about his medication or whether healthcare professionals had fully explained the implications of stopping smoking while taking clozapine.
Ms Lakin observed that practitioners currently have no standardized process for documenting whether patients have been asked about symptoms or potential side effects.
As a result, medical records may contain no indication of whether important discussions took place, making it difficult to determine if appropriate guidance was provided before critical changes in a patient’s lifestyle.
